Education, Science, Technology, Innovation and Life
Open Access
Sign In

Bio-Pharmaceutical Industry R & D Performance Study in China

Download as PDF

DOI: 10.23977/acccm.2021.030107 | Downloads: 32 | Views: 962

Author(s)

Jian Yu 1

Affiliation(s)

1 College of Business Administration, Jiangxi University of Finance and Economics, Nanchang, P.R.C.

Corresponding Author

Jian Yu

ABSTRACT

Bio pharmaceutical industry is a resource-conserving and environment-friendly industry, which is still a new industry in the world. In the process of the development of bio pharmaceutical industry in China, the advantage is the raw material procurement and marketing, the disadvantage is research and development. There are four problems in the research and development of biological medicine industry in China: The shortage of funds, the lack of compound talents, the single source of funds, and the slow development of scientific research. The two models show that the research and development of biological medicine industry in China will have a lagging effect on the development of China's pharmaceutical industry. Four suggestions are put forward: to improve the policy of biological medicine industry, to build a platform for enterprises, to improve the capital market and to train high quality talents.

KEYWORDS

Bio pharmaceutical, R & D investment, Emerging industries

CITE THIS PAPER

Jian Yu. Bio-Pharmaceutical Industry R & D Performance Study in China. Accounting and Corporate Management (2021) 3: 42-54. DOI: http://dx.doi.org/10.23977/acccm.2021.030107.

REFERENCES

[1] Wan, F. (2012). Measurement of industrial agglomeration: innovation based on the empirical research on biological medicine industry in China. (05).
[2] Ye, L. and Feng, G.Z. (2011). Empirical analysis of R & amp; D input and output in China's pharmaceutical industry. modern commercial industry, (19).
[3] Niosi, J., Hanel, P. and Reid, S. (2012). The international diffusion of biotechnology: the arrival of developing countries. Journal of Evolutionary Economics, (4). 
[4] Bianchi, M., Cavaliere, A., Chiaroni, D., Frattini, F. and Chiesa, V. (2010). Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis. Technovation, (1). 
[5] Calero, C., Leeuwen, T.N. and Tijssen, R.J.W. (2007). Research cooperation within the bio-pharmaceutical industry: Network analyses of co-publications within and between firms. Scientometrics, (1). 
[6] Moschini, G. (2006). Pharmaceuticals and Industrial Traits in Genetically Modified Crops: Coexistence with Conventional Agriculture. American Journal of Agricultural Economics, 88(5).
[7] Bianchi, T.S, Allison, M.A. (2009). Large-river delta-front estuaries as natural "recorders" of global environmental change. Proceedings of the National Academy of Sciences, 106(20), 8085-8092.
[8] Lynn, K. and Mytelka. (2006). Pathways and Policies to (Bio) Pharmaceutical Innovation Systems in Developing Countries. Industry & Innovation, (4). 
[9] Linda, A.H. and Sharmistha, B.S. (2006). An analysis of firm-level innovation strategies in the US biotechnology industry. Technovation, (1). 
[10] Kneller, R. (2003). Autarkic drug discovery in Japanese pharmaceutical companies: insights into national differences in industrial innovation. Research Policy, (10). 
[11] Orsenigo, L., Pammolli, F. and Riccaboni, M. (2001). Technological change and network dynamics. Research Policy, (3).

Downloads: 11425
Visits: 164562

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.